Prescription Direction in Medical Cannabis: Guidance for Clinicians and Patients
In the UK, most medical cannabis, legally termed cannabis-based medicinal products (CBPMs), is prescribed by clinicians with specialist expertise, often in the private sector due to limited NHS commissioning. With this reality, issues around prescription direction, where patients are steered toward specific pharmacies or limited product lists, have become important ethical and professional considerations. This guidance aims to clarify what prescription direction means, how it relates to CBPMs, and how clinicians and patients should approach it, grounded in clinical, regulatory and prescribing standards. What Is “Prescription Direction”? ‘Prescription Direction’ refers to any practice in which a healthcare provider influences or obligates a patient to use a particular pharmacy or dispensing service to fulfil their prescription, or restricts which products may be prescribed based on a clinic’s internal formulary rather than clinical considerations alone. For standard prescription-only medicines, and CBPMs alike, once a valid prescription is issued, the patient, not the issuing clinic or prescriber, owns the prescription and has the right to have it dispensed at any appropriate pharmacy. Professional guidance makes no provision for locking prescriptions to a particular dispensing outlet on non-clinical grounds. [1] Legal and Regulatory Framework for Medical Cannabis Prescribing Who Can Prescribe CBPMs In the UK, medical cannabis products (excluding those with a marketing authorisation such as some formulations of Sativex®) are predominantly unlicensed medicines (‘specials’). The law restricts their prescription to doctors on the General Medical Council’s (GMC) Specialist Register. Specialist doctors must also only prescribe within their area of competence and clinical training. [3] NHS England guidance echoes this: while subsequent prescriptions may sometimes be made under shared care arrangements, initial prescriptions must be authorised by a specialist clinician. [2] Regulation of Clinics Prescribing Medical Cannabis Independent clinics that prescribe cannabis-based medicinal products (CBPMs), including those operating solely in the private sector, are regulated by the Care Quality Commission (CQC). The CQC sets out clear expectations for providers prescribing CBPMs, including requirements around clinical governance, prescriber competence, patient safety, informed consent, and compliance with controlled drugs legislation. The CQC guidance confirms that providers must ensure prescribing decisions are clinically justified, appropriately documented, and made in the best interests of the patient, with systems in place to manage risk and avoid conflicts of interest. This includes ensuring that organisational or commercial arrangements do not compromise professional judgement or patient choice in prescribing or supply pathways. [4] Unlicensed Medicines and Clinical Responsibility Unlicensed medicines entail additional responsibilities for prescribers because they have not undergone the full range of regulatory assessments for safety, quality and efficacy. Prescribers must therefore be confident that the product is appropriate for the individual patient, and explain to patients the unlicensed nature of the treatment as part of informed decision-making. [1][5] Supplier and Pharmacy Regulation Although there is no single official UK “list” of pharmacies that can dispense CBPMs, any pharmacy that is properly registered and complies with regulatory standards may dispense them once presented with a valid prescription. Guidance from pharmacy regulators emphasises compliance with controlled drug legislation and safe supply standards for these products. [5] Prescription Direction: Clinical and Ethical Considerations Patient Autonomy and Choice Once a specialist prescriber has written a prescription for a CBPM, the patient retains the right to choose where that prescription is dispensed. Professional standards require clinicians to respect patient autonomy and avoid practices that could restrict choice without clinical justification. The GMC’s prescribing guidance reinforces that clinicians must prescribe only within their professional competence and on clinical grounds. It does not support practices that direct patients to specific suppliers for non-clinical reasons. [1] Clinic Formularies and Product Restrictions Many private medical cannabis clinics operate internal formularies — lists of products they commonly prescribe based on clinician familiarity, supply arrangements, or existing protocols. There may be legitimate clinical reasons to prefer certain products (e.g., formulations with established pharmacological profiles or evidence bases), but clinicians must never refuse to consider other products solely because they are not on an internal clinic list, without clinical reasoning. Clinical judgement during prescribing must focus on the patient’s individual needs rather than operational convenience or commercial preference. This is consistent with all prescribing guidance for individualised care. [1] Responsibilities for Clinicians Do’s for Clinicians Respect patient choice of pharmacy: Once a valid prescription is issued, patients should be informed they may take it to any appropriately registered pharmacy capable of dispensing CBPMs. This respects patient autonomy in clinical care and supply. Provide balanced information on products: Clinicians should discuss the evidence, risks, benefits, and availability of relevant CBPMs to enable informed decision-making. Explain formulary limits transparently: If a clinic’s prescribing experience is concentrated on certain products, explicitly clarify this and discuss why other products may be considered clinically appropriate, if relevant. Follow GMC standards: Ensure prescribing decisions are based on clinical evidence and patient needs, not influenced by commercial relationships or assumptions about pharmacy supply. [1] ✔ Operate within robust clinical governance arrangements: Clinics prescribing CBPMs must meet CQC expectations for safe, effective and patient-centred care, including transparency in prescribing practices and avoidance of commercial influence on clinical decision-making. [4] Don’ts for Clinicians Do not require patients to use a particular pharmacy for non-clinical reasons. Do not imply that prescriptions are “owned” by the clinic or that patients must dispense through a preferred partner. Do not limit prescribing to products on an internal formulary if other products are clinically suitable and available. Any practice that restricts patient choice on non-clinical grounds may undermine professional ethics and patient trust. Rights and Actions for Patients Your Rights as a Patient You have the right to choose the pharmacy that dispenses your prescription, provided it is registered and authorised to supply controlled drugs and CBPMs. [5] A prescription is your legal document and may be taken to any suitable pharmacy. Clinicians must explain the clinical basis for any recommended product, including risks and benefits, to support informed consent. If You Experience Undue Direction If a clinician or clinic appears to restrict your choice of pharmacy or product without clear clinical reasoning: Ask
UTAW Passes Major Motion to Protect Workers Prescribed Medical Cannabis
UTAW passes landmark motion to protect workers prescribed medical cannabis. Learn how unions, employers and patients can tackle stigma and discrimination.
PatientsCann UK Statement on NPCC Guidance for Policing Medical Cannabis Patients
Earlier this week the National Police Chiefs’ Council (NPCC) issued updated guidance instructing police forces across the UK that medicinal cannabis patients should be treated as “patients first, suspects second” when encountered by officers. The guidance explicitly recognises that people in lawful possession of cannabis-based products for medicinal use should be assumed to be patients until proven otherwise, and clarifies that individuals with a valid prescription do not need to hold or present a Cancard, a privately-run card scheme that charges an annual fee and is not a legal requirement under UK law. This development represents a positive and overdue step in aligning policing practice with the legal reality established when cannabis-based medicines were moved to Schedule 2 of the Misuse of Drugs Regulations in November 2018… more than seven years ago. That regulatory change made it lawful to possess cannabis-based products for medicinal use when prescribed by an appropriate clinician. However, as a leading UK medical cannabis patient organisation, PatientsCann UK welcomes the guidance with cautious optimism, because guidance on paper does not automatically translate into consistent, informed practice on the streets. Why Guidance Is Not Enough Without Understanding It is an ongoing reality that many frontline officers still lack accurate awareness of the legal status of medical cannabis: Independent reports and guides have indicated that a significant proportion of officers may still be unaware that medical cannabis can be legally prescribed in the UK, even years after the law changed. (Curaleaf Clinic) Previous force guidance responses under Freedom of Information showed that some police forces did not have internal training or up-to-date briefing materials on this subject, and officers were still being expected to rely primarily on older Home Office circulars and their own discretion. (essex.police.uk) This gap between policy and practice raises serious concerns for patients. The NPCC’s intent, that every police officer should treat someone carrying lawful medical cannabis as a patient first, is commendable. But unless officers are consistently aware of the legal framework, understand how to verify lawful possession, and are trained to apply the guidance, the lived experience of patients may not improve significantly. Clarification and Practical Challenges The NPCC guidance confirms that a Cancard is not legally required for patients with a valid prescription, a vital clarification given the confusion that has surrounded this scheme. Cancard was originally introduced to assist officers in identifying individuals claiming medical need, particularly for those who may be waiting for a prescription or unable to afford one. However, it has always been a discretionary tool, not legal proof of lawful possession. Simply put: 🔹 A card indicating intent or condition does not change the law. That said, PatientsCann UK continues to support patients in carrying necessary documentation (prescription, dispensing label on original packaging, photo ID) where possible, because in the current reality, this often reduces friction in police encounters. Our Concern: Words vs Reality Our central worry remains this: Will the principle of “patients first, suspects second” become the norm, or will we continue to see a default attitude of “guilty until proven innocent”? Guidance is only as effective as the understanding and awareness of the officers applying it. Many patients still report experiences where officers: Misinterpret the law Lack confidence in recognising legitimate prescriptions Treat possession of medical cannabis as inherently suspicious …even when a patient is carrying evidence of lawfully prescribed medication. In some cases this results in needless stress, seizure of medicine, or unnecessary investigations. What PatientsCann UK Calls For To ensure the NPCC’s guidance truly benefits patients, we call for: Rapid, centralised training modules for all frontline officers on the legal status of medical cannabis and the practical application of this guidance. Clear internal briefings in every force that reinforce that lawful possession with a valid prescription is not an offence. Public-facing awareness efforts so patients know what documentation to carry and what their legal rights are. Monitoring and reporting mechanisms to track whether the guidance translates into improved outcomes for patients. We welcome the NPCC guidance as a necessary and positive affirmation of patients’ rights under the law. But we must be vigilant, not just about what the guidance says, but how it is understood and implemented in every police force across the UK. For too long patients have been left to explain something that should be common knowledge within policing. Now, more than ever, we must work together; patients, clinicians, law enforcement, and the wider public, to ensure that legal status and human dignity are recognised equally at every encounter. Mohammad Ismail “Ish” Wasway PatientsCann UK The UK’s Medical Cannabis Patient Organisation
Help Shape The Future of Medical Cannabis
At PatientsCann UK, we represent the voices of patients who rely on safe, effective, and regulated access to medical cannabis. Since its legalisation in 2018, many people have continued to face unnecessary barriers to treatment, from stigma and misinformation to the limited availability of NHS prescriptions. For thousands of patients, private prescriptions remain the only viable route to accessing the medicine they need. That’s why the Department of Health and Social Care’s “Private (non-NHS) Prescribing: Call for Evidence” is such an important opportunity. This review could influence how private prescribing works in the UK, including how cannabis-based medicines are accessed, regulated, and supported by clinicians. Why This Matters The call for evidence invites responses from across the healthcare system, including clinicians, prescribers, pharmacists, healthcare organisations, and patient groups. While the questions are primarily aimed at professionals, it is crucial that patients and carers also share their experiences. By contributing evidence and lived experience, we can help policymakers understand: How private prescribing supports patients who are unable to access NHS treatment. The challenges of affordability, continuity of care, and stigma in private medical cannabis access. The need for greater clinical education and confidence around prescribing cannabis-based medicines. The importance of protecting safe, regulated, and equitable access for all patients. Our Position PatientsCann UK believes that this review must:Protect the right of patients to access regulated medical cannabis safely and affordably.Promote fairness and consistency between NHS and private prescribing pathways.Address stigma and empower clinicians to prescribe based on evidence, not fear.Encourage more research, education, and evidence-based practice across the medical field. This consultation provides a rare chance to shape how the UK approaches private prescribing, and to ensure medical cannabis patients are not overlooked. How to Take Part Your experience is evidence — share it.The Private (non-NHS) Prescribing: Call for Evidence is now open to submissions from individuals and organisations with knowledge or experience of private prescribing. Visit: Private (non-NHS) Prescribing: Call for Evidence – GOV.UKDeadline: 11:59 pm, 4 November 2025 You do not need to answer every question, but you must select Submit at the end for your response to count. How Patients Can Encourage Healthcare Professionals You can play an important role in raising awareness of this consultation within your own care networks. Here are a few ways to help: Start the conversation. Mention the review to your prescribing clinician, pharmacist, or nurse and let them know the deadline. Many professionals may not yet be aware of it. Share the link. Send your clinic, GP practice, or specialist the official GOV.UK consultation page and encourage them to share it with colleagues. Speak to both sides. Whether your care is through a private medical cannabis clinic or the NHS, professionals across both systems can contribute valuable insight on access, patient safety, and clinical challenges. Explain why it matters. Let them know that evidence from healthcare professionals — especially those working with medical cannabis — can directly shape how government policy supports safer and fairer access for patients. Spread awareness. Share our post and tag your clinic, pharmacy, or medical organisation on social media to encourage wider participation. Your voice can help ensure that both patients and healthcare professionals are represented in this important review. Important Note This consultation is separate from the ACMD call for evidence on cannabis-based medicinal products, which focuses on clinical data and scheduling. Both reviews are crucial, and we encourage responses to each. Together, we can ensure that clinicians, patients, and organisations play a leading role in shaping an equitable and evidence-based future for medical cannabis access in the UK. 💚
PatientsCann UK Statement on the ACMD Review of Medical Cannabis
The Advisory Council on the Misuse of Drugs (ACMD) is reviewing cannabis-based products for medicinal use (CBPMs).
Border Patients at Risk: PatientsCann Raises Concerns with UK & Ireland
PatientsCann UK has raised urgent concerns with both the UK and Republic of Ireland (ROI) governments over the risks faced by patients prescribed medicines that are classified as Schedule 1 Controlled Drugs in one jurisdiction but legally prescribed in the other. At present, a prescription issued in the UK, ROI or Crown Dependencies cannot be dispensed across the border if the medicine is considered Schedule 1. More critically, patients cannot lawfully carry these prescribed medicines across the border, even if the crossing is unavoidable in order to travel within their own country. This issue disproportionately affects border communities, where travel across the border is not optional but a daily necessity. For patients in these communities, this creates an impossible situation: return home with their prescribed treatment and risk criminalisation, or forego essential medication. Couriers and healthcare professionals delivering medicines face the same challenge. Practical problems and risks The current situation gives rise to multiple, connected harms: Beyond individual harm, the problem creates wider public-health and administrative issues: increased emergency presentations, greater strain on social care and inequitable access to treatment depending on postcode. What PatientsCann UK is asking for PatientsCann UK has written to the governments of the UK and the Republic of Ireland requesting urgent clarification and guidance, including: The Northern Ireland Office has confirmed that officials are reviewing our letter. PatientsCann UK welcomes this development and will continue to press for clear, rapid action to protect patients who rely on any prescribed medicine. Sal Aziz, Director of PatientsCann UK, said: “Patients should never have to choose between taking their prescribed medicine and risking criminalisation. In practice this is what border communities on the island of Ireland face today. Governments must issue clear operational guidance and protections, urgently, so patients can continue to receive care without fear.” What happens next PatientsCann UK will publish updates as official responses are received. In the meantime, anyone affected by this issue is encouraged to contact PatientsCann UK so we can collate evidence and ensure our representations fully reflect the scale and immediacy of the problem. Please email info@patientscann.org.uk or send us a message on socials (Instagram | X).
This Isn’t a Movement, It’s a Mess
A brutally honest call-in to the UK medical cannabis patient community, about ego, division, and why we’re our own worst enemy.
Network Rail’s Response to Our Concerns: A Call for Fair and Transparent Policy
Network Rail’s policy breaches the Equality Act 2010. PatientsCann UK fights for fair treatment—take action now.
THCa is it legal?
Tetrahydrocannabinolic acid (THCa) is a non-psychoactive cannabinoid found abundantly in raw cannabis plants. Unlike its decarboxylated form, tetrahydrocannabinol (THC), THCa does not produce intoxicating effects. This distinction is crucial for medical cannabis patients, healthcare professionals, and industry experts seeking to understand the therapeutic potential and legal considerations of THCa, particularly within the United Kingdom. Biochemical Nature of THCa THCa serves as the acidic precursor to THC. In its natural state, cannabis plants synthesise cannabinoids in their acidic forms, with THCa being predominant. When exposed to heat through processes like smoking, vaping, or cooking—a reaction known as decarboxylation—THCa loses a carboxyl group, transforming into THC, the compound responsible for cannabis’s psychoactive effects. Therapeutic Potential of THCa Emerging research suggests that THCa may offer several health benefits: Psychoactivity of THCa In its raw form, THCa is non-psychoactive and does not produce the “high” associated with THC consumption. This non-intoxicating nature makes it an attractive option for patients seeking therapeutic benefits without cognitive impairment. However, it’s essential to note that when THCa is heated, it converts into THC, thereby gaining psychoactive properties. Applications of THCa Given its potential therapeutic properties and non-psychoactive nature, THCa is utilised in various forms: Legal Status of THCa in the UK The Advisory Council on the Misuse of Drugs (ACMD) has provided insights into the behaviour and control status of tetrahydrocannabinolic acid (THCa) in its report on consumer cannabidiol (CBD) products. The report highlights that THCa does not significantly convert to Δ9-tetrahydrocannabinol (Δ9-THC) within the human body after ingestion. Additionally, while THCa can decarboxylate into Δ9-THC at temperatures below 100°C, this process requires prolonged exposure; at room temperature, the conversion is negligible. These findings suggest that THCa’s limited potential for in vivo conversion to psychoactive Δ9-THC may influence its regulatory status. The legal framework surrounding THCa in the United Kingdom is complex. While THCa itself is non-psychoactive, it is closely regulated due to its potential to convert into THC when heated. This conversion raises concerns for law enforcement and regulatory bodies. According to the UK’s Misuse of Drugs Regulations 2001, THC is a controlled substance, and any product containing cannabinoids that can be converted into THC may fall under this regulation. In practice, this means that while THCa is not explicitly listed as a controlled substance, its presence in products intended for consumption could be subject to legal scrutiny, especially if there’s a likelihood of decarboxylation into THC. Therefore, products containing THCa are subject to stricter controls and are generally less accessible than CBD products. In the United Kingdom, cannabis and its derivatives are primarily regulated under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001. Cannabis is classified as a Class B controlled drug, making it unlawful to possess, supply, produce, import, or export without appropriate licensing. The legislation defines cannabis to include any part of the plant, excluding mature stalks, fibre, and seeds. Additionally, cannabinoids such as THC are specifically controlled substances. While cannabidiol (CBD) in its pure form is not controlled, products containing other cannabinoids, including THCa, are subject to regulation. The Home Office acknowledges that due to challenges in isolating CBD from other cannabinoids, consumer CBD products may contain varying amounts of controlled substances like THC and THCa. Therefore, any product containing controlled cannabinoids is classified as a Class B controlled drug unless it meets the “exempt product” criteria outlined in Regulation 2 of the Misuse of Drugs Regulations 2001. Exempt Product Criteria For a product to be considered exempt, it must fulfil specific conditions: If a product meets all these criteria, it is not subject to the prohibitions on importation, exportation, production, supply, and possession under the Misuse of Drugs Act 1971. Conclusion THCa represents a promising cannabinoid with potential therapeutic benefits for various medical conditions. Its non-psychoactive nature makes it suitable for patients seeking relief without the intoxicating effects of THC. The sale and distribution of THCa products in the UK occupy a legally ambiguous space. While businesses continue their operations, the potential for legal challenges remains due to the intricate regulatory framework governing cannabis and its derivatives. It is imperative for businesses and consumers to stay informed and consult legal experts when navigating this evolving landscape. References Drug Licensing Factsheet (Cannabis, CBD & Other Cannabinoids) Consumer CBD products report – ACMD Is THCa legal in the UK – r/LegalAdviceUK – Reddit The Legal Weed No One’s Talking About – Vice Disclaimer The information provided in this article is intended for educational and informational purposes only and should not be construed as legal or medical advice. While efforts have been made to ensure the accuracy of the content, however the legal framework surrounding THCa is complex and subject to change. Readers are advised to consult with qualified legal professionals to obtain guidance tailored to their specific circumstances. The authors and publishers disclaim any liability arising from the use or misuse of the information contained herein.
Legal Support for Medical Cannabis Patients in the UK
Since the legalisation of medical cannabis in the UK in 2018, patients have faced numerous challenges in accessing and utilising cannabis-based medicinal products (CBMPs). Despite legal provisions, the landscape remains fraught with limited support, societal stigma, and complex legal hurdles. Organisations like Seed Our Future play a crucial role in advocating for patients’ rights and providing necessary support. Challenges in Legal Support The legal framework surrounding medical cannabis in the UK is complex, creating numerous obstacles for patients seeking treatment. While specialist doctors are legally permitted to prescribe cannabis-based medicinal products (CBMPs), access remains severely limited, forcing many patients to navigate a difficult and often expensive system. One of the primary challenges is the scarcity of NHS prescriptions for medical cannabis. Despite its legal status, NHS doctors rarely prescribe CBMPs, leaving most patients with no choice but to turn to private clinics. However, private prescriptions can be prohibitively expensive, making access to medical cannabis a privilege rather than a right for many who need it. Legal uncertainties further complicate matters. Many patients struggle to understand the exact legalities surrounding the possession and use of their prescribed cannabis, particularly in public spaces or workplaces. Questions about where they can legally consume their medication, how employers should accommodate their needs, and whether they risk law enforcement scrutiny add to the confusion and anxiety patients face daily. A significant barrier to proper legal support is the widespread lack of awareness. Many patients, healthcare professionals, and even service providers do not fully understand the legal rights and regulations governing medical cannabis use. This gap in knowledge often results in patients being misinformed or hesitant to assert their rights, while some service providers may be unwilling to support patients prescribed CBMPs simply due to uncertainty about the legal implications. Societal Stigma Despite its legalisation for medical use, cannabis continues to carry a deep-rooted stigma due to its long-standing association with recreational use and illegality. This stigma affects patients in several ways, often leading to unnecessary challenges and discrimination. One of the most significant issues is public perception. Many medical cannabis patients face judgment or misunderstanding from the public, which can result in social isolation or even outright discrimination. The misconception that all cannabis use is recreational or illicit contributes to this negative outlook, making it harder for patients to openly discuss their treatment or seek support. Employment is another area where stigma creates difficulties. Despite legal protections, employees who use medical cannabis may encounter prejudice or unfair treatment in the workplace. Employers who lack awareness or understanding of medical cannabis laws may view its use as problematic, even when it is prescribed for legitimate health conditions. This can lead to unnecessary workplace conflicts, job insecurity, or even wrongful dismissal. Stigma also extends into the healthcare system itself. Some healthcare professionals remain hesitant to prescribe cannabis-based medicinal products (CBMPs) due to lingering biases or a lack of education on the subject. This reluctance can leave patients struggling to access the treatment they need, forcing them to seek expensive private prescriptions or, in some cases, go without medication entirely. Overcoming these societal barriers requires greater public education, stronger legal protections, and a shift in cultural attitudes towards medical cannabis. Legal Support Resources For patients seeking legal assistance, several law firms and organisations specialise in areas pertinent to medical cannabis use: Organisation/Law Firm Specialties Overview Seed Our Future Legislative Research, Education, Patient Support A national campaign organisation dedicated to legislative and historical research, education through open-source reports, lectures, and articles. They provide support to UK citizens affected by unjust laws and offer assistance to medical cannabis patients facing legal and discrimination cases. Ringrose Law Medical Negligence, Discrimination, and more Offers services in medical negligence and criminal defense, pertinent to medical cannabis patients facing related legal challenges. Their team is equipped to handle cases involving medical malpractice and criminal allegations. While our current list of law firms and organisations offering legal support to medical cannabis patients in the UK is limited, we anticipate its growth as more legal professionals gain a comprehensive understanding of medical cannabis law. As awareness increases and the legal landscape evolves, we are committed to expanding our directory to better serve patients’ needs. We encourage lawyers and solicitors with relevant expertise to contact us, so we can include their services in our list and collectively enhance support for the medical cannabis community. Medical cannabis in the UK remains complex due to limited support and persistent stigma. Organisations like Seed Our Future are essential in advocating for patient rights, providing education, and challenging unjust laws. Supporting such initiatives is crucial for fostering a more informed and compassionate approach to medical cannabis use. Note: This article is for informational purposes only and should not be considered legal advice. For specific legal concerns, consult with a qualified legal professional. Medical Cannabis Employment Medical Cannabis Housing Medical Cannabis Driving Seed Our Future Ringrose Law
